Evidence map›Paper›PMID 40114836›Full record

ReviewTranslational andrology and urology2025

DNA methylation alterations in prostate cancer: from diagnosis to treatment.

Francesco Barletta, Marco Bandini, Giuseppe Ottone Cirulli, Paolo Zaurito, Roberta Lucianò, Francesca Giannese, Giulia Maria Scotti, Caterina Oneto, Nazario Tenace, Federico Scarfò and 9 more

Abstract readReview
In one paragraph

Review in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Francesco BarlettaUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marco BandiniUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giuseppe Ottone CirulliUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Paolo ZauritoUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Roberta LucianòDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesca GianneseCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Giulia Maria ScottiCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Caterina OnetoCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Nazario TenaceDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Federico ScarfòDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marco J MorelliCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Dejan LazarevicCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Francesco De CobelliDepartment of Radiology, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Maurilio PonzoniDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Claudio DoglioniDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giovanni TononCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Giorgio GandagliaUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco MontorsiUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alberto BrigantiUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetics, particularly DNA methylation, plays a crucial role in gene activation and deactivation. Indeed, modification of this pathway has been well described as promoter of cancer development in many settings. Hypermethylation of CpG islands has also been described as a significant epigenetic alteration in prostate cancer (PCa), being associated with gene silencing and tumour progression. Key studies have shown that specific genes, such as

Indexed as

epigeneticsProstate cancer (PCa)translational medicine

Identifiers

PMID40114836
PMCPMC11921382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.